Higher Medicine Received a Letter of Intent (LOI) for the Seed Investment

From Montreal-based Desire Ventures, led by Dr. Assad Aslam, an acclaimed toxicologist and biotech investor, contingent upon a matching investor participating in the round. The proceed from the investment will fund IND-enabling pre-clinical research for the lead p38 inhibitor program for Friedreich's Ataxia.